The Indian Council of Medical Research (ICMR) has dropped Ivermectin and Hydroxychloroquine as drugs for treatment of COVID-19 in their revised 'clinical guidance for management of adult COVID-19 patients'. Drugs like Remdesivir and Tocilizumab can, however, be used under specific circumstances.
Earlier, the WHO had said that COVID-19 patients at high risk of hospitalisation or those with severe disease should be given a combination of two antibody treatments. The WHO Guideline Development Group (GDG) panel recommended treatment combining casirivimab and imdevimab for two specific groups of patients with COVID-19. The first are patients with non-severe COVID-19 who are at highest risk of hospitalisation and the second are those with severe or critical COVID-19 who are seronegative, meaning they have not mounted their own antibody response to COVID-19. The first recommendation is based on new evidence from three trials that have not yet been peer reviewed. The trial show that casirivimab and imdevimab may reduce the risk of hospitalisation and duration of symptoms in those at highest risk of severe disease, such as unvaccinated, older, or immunosuppressed patients.
